A detailed history of Cubist Systematic Strategies, LLC transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 20,300 shares of BBIO stock, worth $579,159. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,300
Previous 20,300 -0.0%
Holding current value
$579,159
Previous $514,000 0.39%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$24.02 - $43.89 $276,494 - $505,217
11,511 New
11,511 $464,000
Q2 2023

Aug 14, 2023

SELL
$13.29 - $18.01 $446,318 - $604,829
-33,583 Reduced 15.36%
185,063 $3.18 Million
Q1 2023

May 15, 2023

BUY
$7.17 - $18.55 $1.52 Million - $3.93 Million
211,721 Added 3057.34%
218,646 $3.63 Million
Q4 2022

Feb 14, 2023

SELL
$6.74 - $11.52 $3.05 Million - $5.21 Million
-452,011 Reduced 98.49%
6,925 $52,000
Q3 2022

Nov 14, 2022

BUY
$7.94 - $12.36 $1.73 Million - $2.69 Million
217,940 Added 90.43%
458,936 $4.56 Million
Q2 2022

Aug 15, 2022

SELL
$5.21 - $12.14 $29,879 - $69,622
-5,735 Reduced 2.32%
240,996 $2.19 Million
Q1 2022

May 16, 2022

BUY
$7.34 - $17.16 $1.35 Million - $3.15 Million
183,439 Added 289.83%
246,731 $2.5 Million
Q4 2021

Feb 14, 2022

BUY
$11.38 - $53.41 $587,845 - $2.76 Million
51,656 Added 443.93%
63,292 $1.06 Million
Q3 2021

Nov 15, 2021

BUY
$46.87 - $64.24 $545,379 - $747,496
11,636 New
11,636 $545,000
Q2 2021

Aug 16, 2021

SELL
$46.47 - $63.93 $173,704 - $238,970
-3,738 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$55.47 - $72.35 $232,308 - $303,001
-4,188 Reduced 52.84%
3,738 $230,000
Q4 2020

Feb 16, 2021

SELL
$38.38 - $71.11 $801,182 - $1.48 Million
-20,875 Reduced 72.48%
7,926 $564,000
Q3 2020

Nov 16, 2020

BUY
$27.2 - $42.19 $783,387 - $1.22 Million
28,801 New
28,801 $1.08 Million

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $4.23B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.